Table 4. Associations between genotypes of rs1017105 and pCR after neoadjuvant chemotherapy in patients with luminal-type locally advanced breast cancer.
| Model | Genotype | pCR | Non-pCR | OR (95% CI)ψ | P value |
|---|---|---|---|---|---|
| Codominant | CC | 9 (18.8) | 39 (81.2) | 1.00 | |
| CT | 4 (9.8) | 37 (90.2) | 1.44 (0.43–4.87) | 0.556 | |
| TT | 2 (28.6) | 5 (71.4) | 2.33 (0.95–5.67) | 0.063 | |
| Dominant | CC | 9 (18.8) | 39 (81.2) | 1.00 | |
| CT + TT | 6 (12.5) | 42 (87.5) | 1.65 (0.54–5.00) | 0.378 | |
| Recessive | CC + CT | 13 (14.6) | 76 (85.4) | 1.00 | |
| TT | 2 (28.6) | 5 (71.4) | 5.80 (1.02–23.49) | 0.014* | |
| Overdominant | CC + TT | 11 (20.0) | 44 (80.0) | 1.00 | |
| CT | 4 (9.8) | 37 (90.2) | 1.26 (0.39–4.01) | 0.698 |
ψ, OR and 95% CI was analysed by logistic regression and adjusted by age, menstrual status, and ER, PR and HER2 status. The common genotype was used as a reference; *, P<0.05. pCR, pathological complete response; OR, odds ratios; CI, confidence intervals; NA, not available; ER, estrogen receptor; PR, progesterone receptor; HER2, epidermal growth factor receptor 2.